Work

Phase Ib/IIa trial of CEND‐1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps4195

Authors: Anup Kasi, Harri Jarvelainen, Raed Moh'd Taiseer Al-Rajabi, Anwaar Saeed, Milind A. Phadnis, Anusha Chidharla, Timothy Schmitt, Sean Kumer, Mazin Mazin Al-Kasspooles, John Ashcraft, Benjamin Martin, Samuel Luka, Mojtaba Olyaee, Amit Rastogi, Scott James Weir, Subhrajit Saha, Prasad Dandawate, Rashna Madan, Weijing Sun, Joaquina Celebre Baranda

Institutions: The University of Kansas Cancer Center, The University of Texas at San Antonio Health Science Center, University of Kansas Medical Center, Peoria campus of the University of Illinois System, University of Kansas, The University of Kansas Health System

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286297014

Cites:

Cited by: 7

Related to: 10